摘要甲状腺激素及甲状腺激素类似物的降脂及减轻体重的作用一直是目前的研究热点.近年的动物研究发现,甲状腺激素受体β(TRβ)激动剂如KB-141、GC-1能够选择性地结合TRβ1而发挥作用,可增加组织耗氧量、降低脂肪含量、减轻体重.此外,这类制剂还能降低低密度脂蛋白-胆固醇、脂蛋白a及甘油三酯等水平,有效降低发生动脉粥样硬化的风险.同时,这些药物能够加快新陈代谢但不增加食物摄入,亦不引起心率增快等心血管不良反应.因此,TRβ激动剂有望成为潜在的新型减肥、降脂药物.

abstractsThe effects of thyroxine and thyroxine analogues on lipid profile and weight loss have been the focus of recent research.Recent animal studies found that thyroid hormone receptors β (TRβ) agonists such as KB-141 and GC-1 could selectively combine with TRβ1,increase tissue oxygen consumption and reduce fat mass and weight.Moreover,the agonists could modulate lipid profile such as low density lipoprotein cholesterol,lipoprotein a and triglyceride,resulting in the reduction of risk of atherosclerosis.In addition to speed up the metabolism without increasing the food intake and the heart rate,the medications do not induce other cardiovascular side effects.Therefore,TRβ agonist may be a new potential type of weight loss and lipidlowering drug.